iN Therapeutics

is a biotech startup based in Korea South, established in 2020. It is a spin-off from the renowned pharmaceutical company, Daewoong Pharmaceuticals, and focuses on medical and pharmaceutical research and development. The company has developed a cutting-edge drug discovery platform for ion channel, Nav1.7 non-opioid analgesic, as well as treatments for hearing loss and neurological diseases. With a decade of experience, iN Therapeutics possesses the world’s premier ion channel evaluation platform and development knowledge, making it a promising player in targeting various CNS (Central Nervous System) diseases. Recently, iN Therapeutics secured a significant KRW26.00B Series B investment on 07 February 2022 from a noteworthy group of investors including Aju IB Investment, DAYLI Partners, E&Investment, InterVest, STIC, Timefolio Asset Management, Shinhan Capital, Kiwoom Investment, and Yuanta Investment. This injection of funds is a testament to the company’s potential and the confidence investors have in its innovative approach to drug development and disease treatment. Overall, iN Therapeutics’ strong industry connections, innovative approach, and strategic partnerships position it as a promising player in the biotechnology and pharmaceutical sectors, with potential for significant growth and impact in the medical field.